IVERIC bio, Inc. (ISEE) financial statements (2022 and earlier)

Company profile

Business Address 8 SYLVAN WAY
PARSIPPANY, NJ 07054
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:382210126131167289297
Cash and cash equivalents26166126131167134222
Short-term investments120144   15575
Other undisclosed cash, cash equivalents, and short-term investments    00 
Receivables 21 144
Other undisclosed current assets6522336
Total current assets:387217129133172296306
Noncurrent Assets
Operating lease, right-of-use asset200
Nontrade receivables  14   
Property, plant and equipment0000133
Long-term investments and receivables      95
Long-term investments      95
Other noncurrent assets 000000
Deferred tax assets, net   23
Other undisclosed noncurrent assets    4  
Total noncurrent assets:202444122
TOTAL ASSETS:389217130137176300429
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:13136681212
Other undisclosed accounts payable and accrued liabilities13136681212
Debt  0    
Deferred revenue and credits 77
Other undisclosed current liabilities15127754719
Total current liabilities:28251313136638
Noncurrent Liabilities
Long-term debt and lease obligation10     
Operating lease, liability10 
Liabilities, other than long-term debt     203206
Deferred revenue and credits 203206
Other undisclosed noncurrent liabilities(1)(0)  125125125
Total noncurrent liabilities:10  125328331
Total liabilities:29251313138394369
Stockholders' equity
Stockholders' equity attributable to parent36119211712438(95)60
Common stock0000000
Additional paid in capital1,040757598546523505466
Accumulated other comprehensive income (loss)(0)0   (0)(0)
Accumulated deficit(680)(565)(481)(422)(485)(599)(406)
Total stockholders' equity:36119211712438(95)60
TOTAL LIABILITIES AND EQUITY:389217130137176300429

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues
(Revenue, Net)
    2105152
Gross profit:    2105152
Operating expenses(115)(89)(61)(65)(102)(246)(175)
Operating income (loss):(115)(89)(61)(65)108(196)(124)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(0)(0)0(0)(0)00
Income (loss) from continuing operations before equity method investments, income taxes:(115)(89)(61)(65)108(196)(123)
Other undisclosed income from continuing operations before income taxes012127221
Income (loss) from continuing operations before income taxes:(115)(88)(59)62109(194)(123)
Income tax benefit 4015017
Net income (loss) available to common stockholders, diluted:(115)(85)(59)63114(193)(106)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(115)(85)(59)63114(193)(106)
Comprehensive income (loss):(115)(85)(59)63114(193)(106)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0  00(0)
Comprehensive income (loss), net of tax, attributable to parent:(115)(85)(59)63114(193)(106)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: